Discussion
AP02, an inhaled form of nintedanib being developed by Avalyn Pharma for idiopathic pulmonary fibrosis (IPF), was generally well tolerated and resulted in higher lung levels of the drug than oral nintedanib, according to findings from two Phase 1 trials. An oral formulation of nintedanib, sold as Ofev,…